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IntracranIal GCTs are morphologically analogous to the germinal neoplasms that arise in the gonads, medi-astinum, or retroperitoneum. Their presence is relative-
ly rare in adult patients, and account for only 0.5–1% of 
all intracranial tumors in adults in Europe and the US,18,41 
with an unexplained higher frequency in Japan and Taiwan 
(1.8–5%).18,25,28,32 Intracranial GCTs are more common in 
children, making up 15% of childhood intra cranial tumors 
in Japan and 7% in the West. Approximately 90% of GCTs 
occur in patients younger than 20 years old, with a peak 
incidence at 11 years of age.18,19,21,25,28,32
According to the World Health Organization clas-
sification23 and the germ cell theory,40 intracranial GCTs 
are divided into 5 histological subtypes of increasingly 
malignant behavior: germinomas, teratomas, ECs, yolk 
sac tumors, and choriocarcinomas. These last 3 are con-
sidered NGMGCTs and typically secrete the oncopro-
teins AFP and hCG.8,21,23 Mixed intracranial GCTs are 
not rare, representing 25–32% of intracranial GCTs.21,32,39 
In fact, only germinomas and teratomas are likely to be 
encountered as pure tumor types.18,21,32,39 This increases 
the risk of sampling error, which is especially serious 
in diagnosing intracranial GCTs because the treatment 
and prognosis are conditioned by the most malignant 
component.18,36 Although germinomas and NGMGCTs 
usually respond to chemotherapy and/or radiation ther-
apy,4,20,21,32 these treatments have little or no effect on the 
teratomatous component, and complete excision has been 
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3 patients, and a large tumor volume in 3 patients. In Group B, 3 patients underwent removal of residual pure mature 
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currently alive (mean follow-up of 9 years); the eighth patient died of postoperative meningitis. Two of the 6 patients 
(33%) with mixed nongerminomatous malignant germ cell tumors died of tumor progression regardless of the timing 
of surgery. 
Conclusions. The results of this study support the belief that microsurgical removal is the only effective treat-
ment for intracranial teratomas. Surgery may be performed as the primary therapy when there is evidence of a nonin-
vasive teratoma, and as a secondary therapy if there is only a partial response to neoadjuvant therapy or if progression 
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shown to be the sole curative treatment for mature terato-
mas.9,18,21,32,36 In consequence, several authors have advo-
cated the surgical removal of a residual mature teratoma 
tissue after NAT for mixed intracranial GCTs.14,15,17,25,33,44
We report on our experience with intracranial terato-
mas in children to investigate the role of resection in the 
treatment of intracranial GCTs that have a histologically 
confirmed teratomatous component.
Methods
Between May 1980 and February 2007, 30 children 
with intracranial GCTs underwent treatment at our institu-
tion. Sixteen patients had pure germinomas and were ex-
cluded from this study. The 14 patients described here har-
bored histologically confirmed teratomas or mixed GCTs 
with a teratomatous component.
The pretreatment diagnosis was based on histopatho-
logical analysis of tissue obtained either from surgical bi-
opsy or resection, or on the results of serum and CSF tumor 
markers (AFP and hCG) to classify tumors in accordance 
with the World Health Organization classification.23
Therapeutic modalities consisted of open surgery for 
tumor removal, oncological treatment (radio- and chemo-
therapy), and CSF diversion, including the use of ventricu-
loperitoneal shunts, external ventricular drains, or ETVs. 
These procedures were often performed on an emergent 
basis because of life-threatening hydrocephalus.
The indications for tumor resection were the presence 
of teratomatous components identified on biopsy sampling 
and/or no detectable tumor markers, or large, poorly toler-
ated tumors with a severe mass effect. Adjuvant therapies 
were administered as part of the primary treatment accord-
ing to the current oncological protocols and based on each 
child’s histopathological diagnosis. The 13 patients who 
underwent tumor resection were divided into 2 subgroups 
according to the timing of tumor removal: Group A com-
prised 10 patients who received surgery as a first-line treat-
ment, and Group B consisted of 3 patients who underwent 
resection for residual teratoma after NAT.
Each patient underwent clinical and radiological 
follow-up, and serum titers of tumor markers were moni-
tored in patients who had tested positive initially. In pa-
tients with tumor progression or relapse, additional treat-
ments such as a “second-look” surgery or an appropriate 
salvage therapy were considered on a case-by-case basis.
Results
The characteristics of the 14 patients are summarized 
in Table 1.
Clinical Findings
The mean age at diagnosis was 10.5 years (126.5 
months) and ranged from 2 days to 219 months; 11 of the 
14 patients were male. Nine patients had tumors located in 
the pineal area, 4 in the suprasellar region, and 1 harbored 
a bipolar lesion (Case 9). The sex predilection related to 
tumor location was striking—all pineal tumors occurred 
in male patients and 3 of 4 suprasellar tumors arose in fe-
male patients. The pretreatment clinical signs are detailed 
in Table 2.
Neuroimaging and Histopathological Examinations
Craniospinal MR imaging was performed in 13 pa-
tients, and CT scanning in 1 patient who received treat-
ment in 1980. The radiological appearance of these lesions 
was heterogeneous in all patients with an association of 
solid and cystic components suggestive of a teratomatous 
component in 10 cases (Fig. 1) and calcifications in 4 cas-
es. Four patients had heterogenous tumors that strongly 
enhanced with contrast addition (Cases 3, 6, 8, and 14).
Tumor marker levels were available in all patients, with 
positive titers of AFP and/or hCG in 6 cases (Cases 3, 6, 8, 
10, 11, and 14). Histopathological tissue analysis was also 
performed in all 14 patients. The teratomatous component 
was identified on primary examination in 12 patients and 
on residual removal after NAT in 2 patients in whom a pure 
germinoma or choriocarcinoma was initially diagnosed 
(Case 9 and 14, respectively). The final diagnosis—based 
TABLE 1
Summary of patient characteristics*
Histological Diagnosis
Case Age (mos), Tumor Tumor 1st Tx & 2nd Tx & 3rd Tx & Current Status,
No. Sex Location Markers Method Initial Secondary Response Response Response FU (mos)
1 128, M pineal none R MT none R, partial NAT, partial –– DF, 292
2 61, M pineal none stereo MT MT R, total –– –– died of sepsis, 1
3 159, M pineal AFP & hCG stereo IT IT R, total NAT, total –– DF, 166
4 140, M pineal none stereo IT G & IT R, partial NAT, partial chemo, partial stable residue, 136
5 92, M suprasellar none R MT & G scar tissue R, partial chemo, partial SR, total DF, 132
6 219, M pineal AFP & hCG endosc MT & EC MT chemo, partial SR, total NAT, partial died of DP, 28
7 10, M pineal none R MT none R, total –– –– DF, 83
8 154, M pineal AFP R MT & EC none R, total NAT, total chemo, partial died of DP, 10
9 207, M both none endosc G MT chemo, partial R, total SR, total stable, 65
10 203, M pineal AFP & hCG R IT none R, total NAT, total –– DF, 23
11 171, F suprasellar AFP & hCG R IT none R, total NAT, total –– DF, 24
12 103, F suprasellar none R MT none R, total NAT, total –– DF, 34
13 2 days, F suprasellar none endosc MT none –– –– –– stable, 22
14 125, M pineal hCG endosc CC MT NAT, partial R, total –– DF, 10
* CC = choriocarcinoma; chemo = chemotherapy; DF = disease free; DP = disease progression; endosc = endoscopy; FU = follow-up; G = germinoma; IT =
immature teratoma; MT = mature teratoma; R = resection; SR = second resection; stereo = stereotactic.
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both on the histological examination and the tumor marker 
levels—was pure mature teratoma in 5 patients (Cases 1, 2, 
7, 12, and 13) and mixed teratoma with malignant compo-
nent in 9 patients. Among the mixed teratomas, there were 
6 NGMGCTs (Cases 3, 6, 8, 10, 11, and 14) and 3 germi-
nomas (Cases 4, 5, and 9). Among the 6 tumors initially 
diagnosed on a biopsy and then surgically verified, only 2 
(33%) had a good correlation with the histological results 
obtained at resection (Cases 2 and 3).
Surgical Procedures
Cerebrospinal fluid diversion procedures were per-
formed in 12 patients as follows: 3 underwent ventriculo-
peritoneal shunt placement, 2 received external ventricu-
lar drains, and 7 patients underwent ETV. Seven biopsies 
were performed—3 via a stereotactic approach and 4 at 
the time of an endoscopic procedure.
Thirteen patients underwent ≥ 1 open surgical proce-
dure, as follows: 6 via an occipitotranstentorial approach, 
4 via a transfrontal-transventricular approach, 2 via a 
subfrontal supraoptical approach, and 1 via a supracere-
bellar-infratentorial route. Ten patients underwent only 1 
open surgical procedure. Two patients required a second 
operation: 1 patient harbored a pineal tumor of a consis-
tency that was too hard to be resected via a transtento-
rial approach and required a transfrontal-transventricular 
route (Case 3), and the other patient had a mixed ger-
minoma and teratoma in the suprasellar region that was 
initially subtotally resected and he underwent a “second-
look” surgery for removal of residual tumor on the floor 
of the third ventricle after chemotherapy (Case 5). One 
patient with an initially diagnosed bipolar germinoma 
(Case 9; Fig. 2) required 3 consecutive surgical interven-
tions after chemotherapy—a transfrontal-transventricular 
approach was performed for residual removal of a ma-
ture teratoma, and then 2 recurrent cystic metastatic ma-
ture teratomas were removed within the posterior fossa. 
Overall, resection was complete for 10 patients (7 in the 
primary resection and 3 after the residual removal) and 
subtotal in 3 patients.
One patient (Case 13) has not yet undergone resec-
tion because she was a newborn at admission with good 
clinical tolerance after CSF circulation was restored by 
endoscopic fenestration of the cyst and ETV. Monitoring 
examination results show a stable tumor 26 months after 
the initial diagnosis.
Surgical Complications
After open surgical removal, 1 patient (Case 2) with 
a mature teratoma died of meningitis in the early postop-
erative period, and 2 patients awoke with delay and have 
moderate mental and motor deficiencies (Cases 1 and 3). 
Three patients experienced transient neurological wors-
ening of preexisting oculomotor disturbances after an 
occipitotranstentorial approach for pineal region tumors. 
One patient needed reoperation to remove a textiloma in 
situ (Case 12). One stereotactic biopsy was complicated 
by intratumoral and ventricular bleeding (Case 3), re-
quiring an emergent external ventricular drainage and an 
open surgical approach for total removal that resulted in a 
good neurological outcome.
Oncological Results
Excluding the patient who died of sepsis, 11 of the 13 
remaining patients (84%) are currently alive with no evi-
dence of disease progression after a mean follow-up of 79 
months (range 10–292 months), but with a persisting sta-
ble tumor in 3 patients. Seven of the 8 patients with pure 
mature or mixed teratomas with germinoma (87.5%) are 
alive and disease free. Two of 6 patients with NGMGCT 
(33%) died because of disease progression: 1 patient from 
Group A (Case 8) and 1 patient from Group B (Case 6).
Group A comprised 10 patients managed with surgi-
cal resection as a primary treatment, as follows: 3 patients 
(Cases 2–4) because a preoperative biopsy had diagnosed 
TABLE 2
Summary of pretreatment signs and symptoms in 14 patients with GCTs*
Tumor Location No. of Patients ICH Coma Oculomotor Disturbance Visual Deficiency Endocrinological Signs Behavioral Changes
pineal 9 9 1 7 1 2 1
suprasellar 4 1 1 — 2 3 1
bipolar 1 1 — 1 — — —
total 14 11 2 8 3 5 2
* ICH = intracranial hypertension.
FIg. 1. Case 7. Axial Gd-enhanced MR image showing a pure 
mature teratoma in the pineal region, with the typical association 
of a solid and a cystic component and well-defined margins.
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a teratoma; 4 patients because they tested negative for the 
presence of tumor markers (Cases 1, 5, 7, and 12); and 3 
patients because of a large tumor volume (Cases 8, 10, 
and 11). In Group A, 2 patients died; 1 because of the 
progression of a malignant secreting component leading 
to leptomeningeal dissemination (Case 8; Fig. 3), and the 
other (who had a pure mature teratoma) because of post-
operative sepsis (Case 2). The 8 remaining patients are 
alive and 7 are free of disease after a mean follow-up of 
114 months.
In Group B, 3 patients (Cases 6, 9, and 14) with pi-
neal tumors received NAT as a primary treatment and 
then underwent resection of a residual tumor. One patient 
(Case 9) was initially diagnosed with bipolar germinoma 
and treated with NAT, but progression of the cystic part of 
the lesion required surgical removal of the tumor, which 
proved to be a mature teratoma (Fig. 2). Two metastatic 
recurrences occurred consecutively in the posterior fos-
sa, requiring 2 surgical procedures more. The patient is 
currently alive with a stable cystic lesion in the posterior 
fossa 65 months after initial diagnosis. One patient (Case 
14), initially diagnosed with a choriocarcinoma, received 
NAT leading to complete normalization of hCG levels, 
but residual tumor revealed on MR imaging 4 months lat-
er required surgical removal of a mature teratoma with no 
evidence of disease 10 months after diagnosis. The third 
patient (Case 6) had a mixed NGMGCT (ECs and mature 
teratomas) that responded to NAT with normalization of 
the AFP levels and underwent complete residual removal 
of a mature teratoma, but spinal relapse of the EC com-
ponent led to death by tumor progression 28 months after 
diagnosis (Fig. 4).
Final Outcome
Among the 11 surviving patients, 8 have had a nor-
mal life and attended school. Three patients have visual 
or oculomotor disturbances and 3 have panhypopituitar-
ism that existed prior to surgery and require hormonal 
replacement. The 2 patients (Cases 1 and 3) who suffered 
the more severe postoperative complications of delayed 
awakening exhibit moderate mental deficiencies and re-
quire special education.
Discussion
Diagnostic and Therapeutic Features of Intracranial GCTs
Intracranial GCT are a heterogenous group of rare 
ce rebral neoplasms18,21,41 including 5 different histologi-
cal subtypes combined within mixed tumors in 25–32% 
of cases.21,32,39 Therefore, pathological investigation of the 
tu mor sample is mandatory before initiation of therapy, 
especially because there is a choice between surgical and 
nonsurgical treatment options.5,11,14,18,21,27,31,32,36,39,41 Although 
less differentiated tumors such as germinomas are usu-
ally highly sensitive to NAT with no need for surgical in-
tervention,20,21,32 pure mature teratomas, arising from the 
differentiated cells of the embryonic tridermal plate, are 
known to respond poorly to NAT, and microsurgery alone 
can be curative.5,9,14,25 With an overall 10-year survival rate 
of 92%, germinomas and mature teratomas belong to the 
good prognosis group in the classification of Matsutani and 
colleagues,32 while secreting lesions typically have a very 
FIg. 2. Case 9. Sagittal T1-weighted MR images with Gd enhancement. A: Initial image showing a peripherally en-
hancing tumor in the pineal region with a large cyst bulging into the third ventricle and a synchronous, small suprasellar 
contrast-enhanced lesion. Both lesions were identified as germinomas on neuroendoscopic biopsy sampling. B: Image 
obtained 4 months after diagnosis, demonstrating tumor progression despite 3 cycles of chemotherapy. C: Postopera-
tive MR image showing total surgical removal of the lesion (achieved via a transfrontal transventricular route).
FIg. 3. Case 8. Axial Gd-enhanced MR image obtained in a 
12-year-old boy showing leptomeningeal dissemination of the 
embryonal carcinoma component of a mixed, malignant, secret-
ing intracranial GCT.
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poor outcome with < 30% of a 3-year survival rate when 
NAT protocols are followed.2,24,31,32,37,44,46 The results in the 
present study are consistent with those in previous reports: 
patients with a pure teratoma or mixed intracranial GCT 
composed of germinoma and teratoma experienced a 10-
year survival rate of 87.5%, whereas 2 of 6 patients (33%) 
with mixed teratoma and NGMGCT rapidly died of disease 
progression (Table 1).
In cases of teratomas, which account for 18–20% of 
all intracranial GCTs,18,21,31,32 a pretreatment biopsy for 
diagnosis could be avoided if typical clinicoradiological 
features are identified. These are not secreting tumors 
and MR images typically show nonhomogenous images 
of mixed intensity and heterogenous contrast enhance-
ment with frequent large cysts and areas of calcification 
(Fig. 1).7,32,48 The characteristics of young age, male pre-
dominance, and pineal preferential location are also car-
dinal features,11,21,32,41 as in the present study: tumors in 
9 patients (64.3%) arose in the pineal region and clear 
radiological signs of teratoma were seen in 10 patients 
(71%). All of our patients were within the first 2 decades 
of life, and we observed a male-to-female ratio of 3:1. 
The 3 cases of pure mature teratoma occurred in younger 
patients at 0, 10, and 61 months of age. The identifica-
tion of these elements of noninvasive diagnosis is crucial 
because biopsy sampling is risky and does not always 
yield a good specimen in cases of teratomas.12,27,35,36 The 
reliability of noninvasive diagnostic tools is particularly 
illustrated in Case 9 in our study. In this patient, neuro-
radiological findings strongly indicated the presence of a 
teratoma (Fig. 2), later confirmed at surgery, despite the 
fact that neuroendoscopic biopsy had initially diagnosed 
the lesion as a pure germinoma. 
Indications for Surgical Removal of Intracranial Teratomas
Complete microsurgical removal has been shown to 
be the only curative treatment for pure teratomas.8,9,14,25, 
29,32,33,44 The use of resection as the only therapy avoids 
both the particularly high risks of stereotactic biopsy in 
the pineal region and the adverse effects of adjuvant ther-
apies, especially in prepubescent patients.11,18 Matsutani et 
al.32 reported a 10-year survival rate of 92.9% in patients 
with pure mature teratomas who underwent surgical exci-
sion only, and a 10-year survival rate of 71% in patients 
with malignant teratomas who underwent extensive sur-
gery followed by radiation therapy and no chemotherapy. 
In the present study all patients with pure mature or im-
mature teratomas who underwent resection as the sole 
therapy are alive and free of disease at a mean follow-up 
of 9 years, with the exception of 1 patient who died of 
meningitis. Radical treatment is strongly advocated for 
intracranial teratomas because malignant transformations 
are not rare,9,23 and have been reported in 4 of 27 cases of 
teratomas by Matsutani et al.,32 and 6 of 7 patients with 
pure teratoma in Hoffman and colleagues’18 study.
In addition, open surgery is the only way to obtain an 
accurate histological diagnosis because teratomas are fre-
quently a component of mixed tumors.11,14,18,21,27,31,32,36,39,41 
Determination of the tumor type based on biopsy risks 
misdiagnosis if there are other tumor components that were 
not sampled and that require a specific treatment,26,27,32,36 
whereas resection3,11,17,18,41 provides a large sample of the 
tumor,41 minimizing the risk of missing some component.32 
Furthermore, stereotactic biopsy in the pineal region car-
ries a particularly high risk of bleeding complications, 
nearly 21%,12 with an overall mortality rate of 1.3–1.8% 
and a severe persistent morbidity rate of 0.8–4.5%,10,12,27,36 
increasing with harder, mature teratomas that resist needle 
penetration.36 Neuroendoscopic biopsy is therefore indicat-
ed because sampling is performed under visual control.6,34 
The obstructive hydrocephalus can be managed with ETV, 
and the cysts managed by opening and fenestration.6 Neu-
roendoscopic biopsy is characterized by the lowest level of 
accuracy because of the small quantity of biopsy material 
extracted.47 In the present study, mixed intracranial GCTs 
were present with a high rate of 64.3%. Seven biopsies 
were performed—3 via a stereotactic approach and 4 via 
an endoscopic approach. Good histological correlation was 
achieved in only 2 (33%) of 6 surgically verified cases. The 
identification of the teratomatous component was delayed 
until surgical removal of the residual tumor after NAT 
in 2 patients in Group B (Cases 9 and 14; Fig. 2). Such 
cases of malignant GCTs for which there is no histologi-
cal evidence of teratoma on the initial examination, but in 
which the patients have normalized tumor marker levels 
after NAT and require removal of residual mature teratoma 
after NAT, have been described both extra- and intracra-
nially.14,25,44 This phenomenon is called “growing teratoma 
syndrome.”16,29,30,33,45 The growth of a mature teratoma after 
NAT could be related to the chemoresistance of a benign 
FIg. 4. Case 6. Sagittal T1-weighted MR images with Gd enhancement. A: Initial image showing a heterogenous 
tumor in the pineal region diagnosed as a mixed mature teratoma with EC after neuroendoscopic biopsy. B: Image 
obtained 8 months later showing a partial response obtained after 4 cycles of chemotherapy with a stable residual 
tumor. C: Postoperative image after complete resection of the residual tumor via an occipitotranstentorial approach. 
Final histological examination of the surgical specimen revealed pure mature teratoma.
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component within a mixed malignant GCT or result from 
paradoxically increasing growth as the cellular competi-
tion from the malignant element disappears.29,38
The prognosis of mixed teratomas varies widely de-
pending on the nature of the most malignant component. 
However, even secreting components may benefit from ag-
gressive surgery because cytoreductive intervention will 
improve the response to adjuvant therapy and allow lower 
doses to be used.8,11 In addition, the poor prognosis of 
mixed malignant, secreting, intracranial GCTs improves 
with the combination of NAT followed by removal of re-
sidual teratoma when the patient tests negative for tumor 
markers.1,4,14,15,17,24,25,30,33,37,44 In 3 recent studies,14,25,44 the 
5-year survival rate was increased to 70–100% for intra-
cranial malignant GCTs treated with NAT first, followed 
by residual removal of a mature teratoma or scar tissue. 
In the present study, we also identified 2 cases of growing 
teratoma syndrome (Cases 9 and 14; Fig. 2) arising from 
a germinoma and a choriocarcinoma. Both patients are 
currently alive with no evidence of disease progression 
17 months later.
Finally, resection can lead to decompression of adja-
cent structures, thus obviating the need for shunt placement 
in cases of pineal region tumors, or relieving compression 
of the optic pathways in cases of suprasellar tumors.19
Surgical Approaches to Intracranial Teratomas
Like their extracranial counterparts, intracranial tera-
tomas tend to arise at the midline: 81–95% are located along 
an axis from the suprasellar cistern to the pineal region.21,32 
Despite this critical location in deep-seated regions of the 
brain, the refinements of microsurgical techniques within 
the past 30 years have made open surgical approaches to 
these regions safe procedures with a low morbidity rate (< 
10%) and no operative deaths.3,11,14,18,26,32,41–43 Our results em-
phasize the recent advances in microsurgical techniques. 
We performed 17 open surgical procedures. All incidences 
of death and complications related to open surgery in our 
patients occurred in the 3 patients who underwent surgery 
prior to 1992: 1 patient died from postoperative meningitis, 
and 2 patients with delayed postoperative awakening suf-
fered permanent mental deficiencies. In our more recent 
cases, only 3 patients sustained transient neurological de-
terioration.
Given the higher prevalence of these lesions in the 
pineal location, the occipitotranstentorial and infratento-
rial supracerebellar approaches are preferentially utilized 
for surgical removal of intracranial teratomas.3,15,22,26,42,43 
The choice of approach depends on the lesion’s size and 
precise location within the pineal area, and its relationship 
to the ventricular system, the median line, and the sple-
nium.3,15 A careful analysis of the morphological features 
and relationships of the tumor on MR imaging is decisive 
for determining the surgical approach. Magnetic resonance 
angiography focusing on the deep veins may be helpful in 
this respect. The supracerebellar approach is indicated for 
small- or medium-sized tumors located in the midline and 
below the galenic system and the splenium of the corpus 
callosum, but used to be performed with the patient in a 
sitting position,3,42,43 while the occipitotranstentorial ap-
proach used currently is preferred for larger tumors ex-
tending laterally and superiorly above the tentorium and is 
advantageous because it adds no risk of air embolism.15,26 
A better field of view in the superoinferior direction al-
lows an easier access to lesions at the superior cerebellar 
surface or with downward extension toward the fourth ven-
tricle.26 Retraction of the occipital lobe is almost unneces-
sary if an adequate amount of CSF is aspirated from the 
interhemispheric and ambient cisterns. Therefore, the latter 
technique was primarily used in the present study (6 cases): 
all surgeries were performed with the patient in the prone 
position, allowing total or subtotal removal of most pineal 
teratomas. We performed a transventricular approach in 2 
cases of large pineal tumors of hard consistency extending 
anteriorly into the third ventricle (Cases 3 and 9). Indica-
tions for the transfrontal and subchoroidal approaches are 
the tumor’s extension into the posterior and middle part of 
the third ventricle, and when an anterior portion reaches 
near the foramen of Monro region, as was true of the le-
sion in Case 9. The tumor was located entirely within the 
third ventricle, with the cystic part roofed by the foramen 
of Monro and the solid portion located strictly anterior to 
the quadrigeminal plate and below the splenium. Either of 
the preferred approaches to the pineal region in this case 
would have led to a partial resection, with a high risk of 
injury to the corpus callosum and the deep venous system. 
The obstructive hydrocephalus with considerable enlarge-
ment of the foramen of Monro bilaterally allowed a wide 
surgical exposure with a transfrontal transventricular route 
leading to complete surgical removal with no complica-
tions in this case (Fig. 2).
Limits and Timing of Resection
Mature teratomas are typically firmly adherent to 
neighboring tissues,7,32 especially in cases of repeated sur-
gery. Gamma Knife radiosurgery has been successfully 
applied as an alternative treatment in higher risk patients 
in 3 cases of residual or recurrent intracranial GCT with-
out elevated tumor markers.7 Given these preliminary re-
sults, the strategy of planned combined micro- and radio-
surgical treatment of large intracranial teratomas should 
be considered either as a first therapeutic option or for 
recurrent or growing residual tumors, avoiding the risks 
related to attempting resection of small and adherent tu-
mor pieces. The patient in Case 9 in our series could also 
benefit from Gamma Knife surgery for a recurrent meta-
static teratoma in the posterior fossa.
The strong curative value of resection in cases of 
mixed teratoma with malignant component must be modu-
lated by 3 predictive factors.12,14,15,25,44 The main oncologi-
cal prognostic factor is determined by the initial histologi-
cal diagnosis: NGMGCT components are associated with 
a poorer outcome than germinoma32,44 and require an ag-
gressive pre- and postoperative chemotherapy and radio-
therapy regimen. Case 6 is particularly illustrative: despite 
complete excision of residual mature teratoma tissue after 
chemotherapy for an initially diagnosed EC, the patient 
eventually died of progression of the malignant compo-
nent. Another negative prognostic factor is the absence of 
complete normalization of tumor marker levels when the 
residual tumor is removed. Weiner et al.44 suggested that 
delayed surgical removal of residual tumor should only be 
J. Neurosurg.: Pediatrics / Volume 2 / November 2008
Surgical treatment of intracranial teratomas
337
performed when tumor markers have returned to normal 
levels. Kochi and colleagues25 consider the presence of vi-
able tumor cells within residual tumor tissue as a source of 
recurrence or progression; authors of previous extracranial 
studies have recommended their excision.13
In the context of delayed surgery, it appears to be 
of great value to check for evidence of preoperative dis-
semination on MR imaging and to assess serum tumor 
markers. If the markers have normalized, then surgical 
intervention should be undertaken as soon as possible to 
reduce the delay between the end of NAT and surgery, 
thus avoiding tumor regrowth in the interval.
Conclusions
Our results support the notion that surgical removal 
is the only curative treatment for intracranial teratomas 
because of their chemo- and radioresistance. Surgery may 
be performed as a first-line therapy when the results of 
noninvasive diagnostic investigations suggest the presence 
of a teratoma, or after oncological therapy for removal of 
residual tumor, improving the prognosis of patients with 
mixed malignant GCTs. In cases of mixed GCT, however, 
the final outcome depends on the oncological status at the 
time of surgery. Several conditions should then be taken 
into consideration and are summarized in a flowchart in 
Fig. 5.
Because of the high rate of mixed tumors and the poor 
correlation between histological biopsy tissue sampling 
and the results of surgical tissue examination, both patho-
logical diagnosis and treatment of intracranial teratomas 
can be performed optimally through a single procedure 
at the time of an open surgical approach. Magnetic reso-
nance imaging analysis will be the determining factor in 
choosing the surgical approach, even if the occipitotrans-
tentorial route is preferred because of a wider exposure. 
The complication rate can be reduced by the use of modern 
microsurgical techniques, and is acceptable when sur gical 
removal is the only available treatment.
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